Retatrutide 10 mg – GLP3-R3TA, Veyrona Labs
,

Retatrutide (RETA) – 10 mg / 20 mg / 30 mg

Price range: 63,90 € through 129,90 €

Retatrutide (RETA), supplied as GLP3-R3TA, is a research peptide studied mainly in weight regulation, appetite and metabolism.

In simple terms, researchers are investigating how three connected signals may influence hunger, the way nutrients are processed and the amount of energy the body uses.

Research areas: Body-weight regulation · Appetite · Glucose and lipid metabolism

RECOMMENDED LABORATORY ACCESSORY
Bacteriostatic Water 3 / 10 ml
Bacteriostatic Water (BAC)Optional laboratory diluent. Confirm compatibility with the material documentation.View product details →
SKU: GLP3-10MG Categories: ,
Veyrona Labs Research Profile

Retatrutide (RETA) — GLP3-R3TA (LY3437943)

An investigational single-molecule agonist engineered to engage the GIP, GLP-1 and glucagon receptors—three interconnected signalling systems studied in metabolic regulation, energy balance and glucose homeostasis.

Technical product dataQuality and identity at a glance
Purity / analysis10 mg batch RT10-26001: 99.7% purity (HPLC), measured content 10.43 mg; other variants are batch-specific
Physical formLyophilized research material
Declared content10 mg / 20 mg / 30 mg — selectable variant
Packaging1 sealed laboratory vial
Peptide typeModified triple GIPR / GLP-1R / GCGR agonist peptide
Molecular formulaC221H342N46O68
Molecular weight4731.3 g/mol
CAS number2381089-83-2
Storage — unopened powderKeep the sealed freeze-dried vial at −20 °C, dry and protected from light. Let the closed vial reach room temperature before opening to limit condensation.
Storage — after mixing with BAC waterAfter preparation with bacteriostatic water, keep refrigerated at 2–8 °C and protected from light. Do not freeze; minimize repeated warming and cooling.
Solubility / reconstitution10 mg: Bacteriostatic water — 1 ml per vial
20 mg: Bacteriostatic water — 2 ml per vial
30 mg: Bacteriostatic water — 3 ml per vial
Scientific Background

What is Retatrutide (RETA / GLP3-R3TA)?

GLP3-R3TA, also designated LY3437943, is a synthetic peptide developed as a triple agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Unlike single GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists, its design adds glucagon-receptor activity to the incretin signalling profile.

The molecule has progressed from early pharmacology and Phase 1 studies into a broad Phase 3 clinical-development programme. Published research now covers receptor activity, dose response, body-weight change and a wide range of cardiometabolic markers.

Three Complementary Pathways

Mechanism of Action

Retatrutide is designed to activate three class-B G-protein-coupled receptors. Scientific interest centres on the balance of these signals rather than on any receptor acting in isolation.

GIP

GIP receptor

GIPR signalling participates in nutrient-responsive endocrine activity, including glucose-dependent insulin secretion. In a triple-agonist system it is studied alongside GLP-1R and GCGR activity as part of an integrated metabolic response.

GLP-1

GLP-1 receptor

GLP-1R activation is associated with glucose-dependent pancreatic signalling, central appetite pathways and effects on gastric emptying. The relative contribution of each pathway depends on exposure, receptor balance and the experimental model.

GCG

Glucagon receptor

GCGR signalling adds hepatic substrate-mobilisation and energy-expenditure biology. Its inclusion distinguishes retatrutide from single- and dual-incretin approaches and is a central focus of mechanistic research.

Integrated signalling: preclinical and clinical research examines how combined receptor engagement influences appetite-related neural signalling, glucose regulation, lipid handling, hepatic metabolism and total energy balance. Observed clinical outcomes cannot be assigned to one receptor alone.
Areas Under Active Investigation

Key Research Areas

Body weight and energy balance

Dose-dependent changes in body weight, waist circumference and energy-balance endpoints have been central outcomes in obesity trials.

Glycaemic regulation

Studies in type 2 diabetes examine HbA1c, fasting glucose and the interaction of incretin and glucagon-receptor signalling.

Liver fat and lipid metabolism

Dedicated analyses have evaluated liver-fat content, triglycerides and other markers of metabolic liver health.

Cardiometabolic risk markers

Clinical programmes include blood pressure, non-HDL cholesterol, inflammation-related markers and cardiovascular outcomes.

Human Clinical Evidence

What Does the Research Show?

The studies below present results from defined clinical-trial groups together with their duration, dose and study design, making the development programme easy to compare at a glance.

Phase 2 obesity trial · 338 participants−24.2%

Mean body-weight change at 48 weeks

The 12 mg group reached a mean change of −17.5% at 24 weeks and −24.2% at 48 weeks. The placebo group changed by −2.1% at 48 weeks. The trial was randomized, double-blind and placebo-controlled.

TRIUMPH-4 · Phase 3 topline data−28.7%

Mean body-weight change at 68 weeks

Reported for the 12 mg group among participants with obesity or overweight and knee osteoarthritis. WOMAC pain and physical-function endpoints were also assessed. Full peer-reviewed publication should be distinguished from company-reported topline results.

TRIUMPH-1 · Phase 3 topline data−28.3%

Mean body-weight change at 80 weeks

In participants without diabetes, 45.3% of those assigned to 12 mg achieved at least 30% body-weight reduction. A prespecified higher-BMI extension continuing to 104 weeks was reported separately.

TRIUMPH-2 · Phase 3 topline data−20.8%

Mean body-weight change at 80 weeks

Reported for the 12 mg group in adults with type 2 diabetes and obesity or overweight, alongside mean HbA1c reductions of up to approximately 1.6 percentage points across the reported programme analysis.

Evidence in context. Gastrointestinal adverse events—including nausea, diarrhoea, vomiting and constipation—were the most frequently reported events in clinical trials and were generally dose-related. Phase 3 topline announcements provide important data, but detailed peer-reviewed publications remain the stronger basis for evaluating methods, subgroup effects and limitations.
Selected Literature

Research & Publications

  1. Urva S et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist: early clinical pharmacology and proof of concept. Cell Metabolism (2022). PubMed record.
  2. Rosenstock J et al. GLP3 in people with type 2 diabetes: randomized Phase 2 trial. The Lancet (2023);402:529–544. PubMed record.
  3. Jastreboff AM et al. Triple–Hormone-Receptor Agonist GLP3 for Obesity — A Phase 2 Trial. New England Journal of Medicine (2023);389:514–526. Full publication.
  4. Sanyal AJ et al. Triple hormone receptor agonist GLP3 for metabolic dysfunction-associated steatotic liver disease: Phase 2 substudy. Nature Medicine (2024). PubMed record.
  5. TRIUMPH clinical programme. Current Phase 3 studies and registered protocols. ClinicalTrials.gov.

Phase 3 items are clearly identified as company-reported topline data or peer-reviewed publications, so readers can see the source and stage of each result.

Batch-Specific Transparency

Independent Laboratory Testing

The analytical panel below presents the tested 10 mg batch RT10-26001. Every additional strength and production lot is linked to its own batch identifier and laboratory report.

View Batch Lab Results

BatchRT10-26001
Declared10 mg
Measured10.43 mg
Purity99.7%
Test date14 Aug 2026
ScopeOne batch
Research Status · Important Information

Investigational molecule in Phase 3 development

For laboratory and analytical research only. Not for human or veterinary use.

Weight 0,01 kg
Strength

10 mg, 20 mg, 30 mg

1 review for Retatrutide (RETA) – 10 mg / 20 mg / 30 mg

  1. Rated 5 out of 5

    peptidy –

    Almost nobody si testing for endotoxins..Thank you!

Add a review

Your email address will not be published. Required fields are marked *

Related products

Welcome to Veyrona Labs
Scroll to Top